In vivo CRISPR/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells

In vivo CRISPR/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells

Fusion oncogenes (FO) are common in cancers, but specific targeting of these chimeric genes are challenging. Here the authors report a CRISPR/Cas9 strategy that targets two intronic regions to disrupt the FOs in cancer cells and show that this approach reduces tumour growth and prolongs survival in...

Full description

Saved in:
Bibliographic Details
Main Authors: M. Martinez-Lage, R. Torres-Ruiz, P. Puig-Serra, P. Moreno-Gaona, M. C. Martin, F. J. Moya, O. Quintana-Bustamante, S. Garcia-Silva, A. M. Carcaboso, P. Petazzi, C. Bueno, J. Mora, H. Peinado, J. C. Segovia, P. Menendez, S. Rodriguez-Perales
Format: article
Language:EN
Published: Nature Portfolio 2020
Subjects:
Science
Q
Online Access:https://doaj.org/article/734f530d0a9c4f49995b0d8094e4f389
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Fusion oncogenes (FO) are common in cancers, but specific targeting of these chimeric genes are challenging. Here the authors report a CRISPR/Cas9 strategy that targets two intronic regions to disrupt the FOs in cancer cells and show that this approach reduces tumour growth and prolongs survival in animal models of cancer.

Similar Items